Differences in survival for patients with metastatic colorectal cancer by lines of treatment received and stage at original diagnosis.

摘要: Summary Objective Few published studies have examined survival rates for patients with metastatic colorectal cancer (mCRC) by number of lines treatment received or stage at diagnosis. This study aims to evaluate and numbers in USA mCRC managed care patients. Methods To the impact chemotherapy/biological on mCRC, adults a diagnosis CRC between 1 January 2005 31 May 2010 were identified from Oncology Management registry. Registry data included date. Patients IV original development metastasis included. Linked healthcare claims large database used identify after patient characteristics. The population was enrolled commercial health insurance programme, 10% > 65 years age. categorised (0, 1, 2, 3+) (0–3, 4, unknown). Survival following evaluated using Cox proportional hazards models controlling treatment, disease stage, other characteristics. Results Study commercially insured adult patients, ≥ 18 years age (n = 598, mean 54, 56% male), 16% which did not receive therapy becoming metastatic, 33% only line treatment. Average follow-up 653 days, 19% died during period. Mean unadjusted length 516, 511, 627 930 days who 0, 2 3+ respectively. In model, geographical region variable significantly associated (p < 0.05). Conclusion Lines statistically development.